SMO and cancer: Targeting CSNK1D with compounds such as SR-3029 and CK1D008 may, therefore, be a promising future strategy to treat cancer patients with acquired or a priori resistance to SMOi, and to hopefully reduce severe side effects known to be caused by established anti-SMO drugs.